Global Markets Direct’s, 'Cardiometabolic Disease - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cardiometabolic Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cardiometabolic Disease. Cardiometabolic Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Cardiometabolic Disease. - A review of the Cardiometabolic Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cardiometabolic Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Cardiometabolic Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Cardiometabolic Disease pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Cardiometabolic Disease - Pipeline Review, H2 2013 Table of Contents Table of Contents 2 List of Tables 3 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Cardiometabolic Disease Overview 6 Therapeutics Development 7 An Overview of Pipeline Products for Cardiometabolic Disease 7 Cardiometabolic Disease Therapeutics under Development by Companies 9 Mid Clinical Stage Products 10 Comparative Analysis 10 Discovery and Pre-Clinical Stage Products 11 Comparative Analysis 11 Cardiometabolic Disease Therapeutics - Products under Development by Companies 12 Companies Involved in Cardiometabolic Disease Therapeutics Development 13 Torrent Pharmaceuticals Limited 13 Zafgen Inc. 14 miRagen Therapeutics, Inc. 15 Cardiometabolic Disease - Therapeutics Assessment 16 Assessment by Monotherapy Products 16 Assessment by Route of Administration 17 Assessment by Molecule Type 19 Drug Profiles 21 TRC-150094 - Drug Profile 21 Product Description 21 Mechanism of Action 21 RandD Progress 21 Cardiometabolic Disease Program - Drug Profile 23 Product Description 23 Mechanism of Action 23 RandD Progress 23 MGN-5804 - Drug Profile 24 Product Description 24 Mechanism of Action 24 RandD Progress 24 DS-102 - Drug Profile 25 Product Description 25 Mechanism of Action 25 RandD Progress 25 DS-103 - Drug Profile 26 Product Description 26 Mechanism of Action 26 RandD Progress 26 messenger RNA Therapeutics Program - Drug Profile 27 Product Description 27 Mechanism of Action 27 RandD Progress 27 Cardiometabolic Disease Therapeutics - Discontinued Products 28 Cardiometabolic Disease Therapeutics - Dormant Products 29 Appendix 30 Methodology 30 Coverage 30 Secondary Research 30 Primary Research 30 Expert Panel Validation 30 Contact Us 31 Disclaimer 31
List of Tables
Number of Products Under Development for Cardiometabolic Disease, H2 2013 7 Products under Development for Cardiometabolic Disease - Comparative Analysis, H2 2013 8 Number of Products under Development by Companies, H2 2013 9 Comparative Analysis by Mid Clinical Stage Development, H2 2013 10 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 11 Products under Development by Companies, H2 2013 12 Torrent Pharmaceuticals Limited, H2 2013 13 Zafgen Inc., H2 2013 14 miRagen Therapeutics, Inc., H2 2013 15 Assessment by Monotherapy Products, H2 2013 16 Assessment by Stage and Route of Administration, H2 2013 18 Assessment by Stage and Molecule Type, H2 2013 20 Cardiometabolic Disease Therapeutics - Discontinued Products 28 Cardiometabolic Disease Therapeutics - Dormant Products 29
List of Figures
Number of Products under Development for Cardiometabolic Disease, H2 2013 7 Products under Development for Cardiometabolic Disease - Comparative Analysis, H2 2013 8 Products under Development by Companies, H2 2013 9 Mid Clinical Stage Products, H2 2013 10 Discovery and Pre-Clinical Stage Products, H2 2013 11 Assessment by Monotherapy Products, H2 2013 16 Assessment by Route of Administration, H2 2013 17 Assessment by Stage and Route of Administration, H2 2013 18 Assessment by Molecule Type, H2 2013 19 Assessment by Stage and Molecule Type, H2 2013 20